Project Grant R01HL183792
Award Date 8/15/26
Completion Date 4/30/30
Dollars Obligated $466K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
East Lansing, MI 48824, USA
Similar Awards
- The National Heart, Lung, and Blood Institute awarded Michigan State University (doing business as Henry Ford Health+Michigan State University Health Sciences) $232,156 on August 10, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop physics- and image-based patient-specific computer models that predict the risk of left ventricular outflow tract obstruction in transcatheter mitral valve replacement procedures. The research addresses a critical limitation in current...
- The National Heart, Lung, and Blood Institute awarded The Leland Stanford Junior University $198,728 on March 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate the molecular mechanisms of mitochondrial calcium extrusion in ischemic heart disease. The research focuses on TMEM65, an emerging target implicated in mitochondrial sodium-dependent calcium extrusion (MNCX). Ischemia-reperfusion injury damages cardiac tissue partly through aberrant mitochondrial...
- The National Heart, Lung, and Blood Institute awarded Baylor College of Medicine $625,035 on August 17, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to support research into the molecular mechanisms of mitochondrial calcium exchange in the heart. The research addresses mitochondrial calcium overload, which triggers cell death and tissue damage during ischemia-reperfusion injury—a secondary phase of cardiac damage that can account for up to 50 percent of final infarct...
- The National Heart, Lung, and Blood Institute awarded the Regents of the University of Michigan $759,670 on August 11, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate metabolite-driven epigenetic regulation in cardiac repair following myocardial infarction. The research examines how disruptions in metabolic pathways deplete critical metabolites—including acetyl-CoA and α-ketoglutarate—required for epigenetic and RNA-modifying enzymes. The project...
- The National Heart, Lung, and Blood Institute awarded the University of Pittsburgh $1,088,692 on August 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to support research on interorganellar calcium signaling in health and disease. The award funds basic research examining how calcium signaling across the plasma membrane, endoplasmic reticulum, mitochondria, and lysosomes generates localized calcium microdomains that regulate transcriptional and metabolic programs...
- The National Heart, Lung, and Blood Institute awarded the Regents of the University of Michigan $724,200 on July 10, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate endothelial cell fate switches and dysfunction driven by fibrotic matrix remodeling. The research uses mouse models and an in vitro human microphysiological system of arteriole and venule-scale microvessels embedded within tunable stromal mimetic matrices to demonstrate how fibrotic physical cues...
- The National Heart, Lung, and Blood Institute awarded Michigan State University (doing business as Henry Ford Health+Michigan State University Health Sciences) $1,099,000 on June 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop precision circadian medicine solutions for shift workers managing shift work disorder. The award funds research scaling digital health technologies, including consumer-based wearables, to track and manage circadian rhythms in nightshift...
- The National Heart, Lung, and Blood Institute awarded the Regents of the University of Michigan $724,971 on August 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate macrophage 12-lipoxygenase signaling as a therapeutic target in heart failure with preserved ejection fraction (HFPEF). The research program establishes 12-lipoxygenase (12-LOX), an enzyme that converts arachidonic acid into bioactive lipid mediators, as a master regulator of HFPEF progression...
- The National Heart, Lung, and Blood Institute awarded Michigan State University (operating as Henry Ford Health+Michigan State University Health Sciences) $1,556,310 on July 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop an inhaled powder formulation of vonoprazan as a novel inhalation therapy for idiopathic pulmonary fibrosis treatment. The award funds research to repurpose vonoprazan, an existing proton pump blocker, as an aerosol-delivered treatment...
- The National Heart, Lung, and Blood Institute awarded the Regents of the University of Michigan $1,026,853 on September 12, 2025, under the Cardiovascular Diseases Research program (CFDA 93.837) to define the molecular basis of thrombospondin-1-induced fibro-fatty diaphragm remodeling as a driver of obesity-associated respiratory dysfunction. The research investigates how diet-induced obesity promotes diaphragm weakness through fibro-adipogenic progenitor cell expansion and extracellular...